LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, reported that as of the close of the market on December 3, 2010, CytRx is in compliance with all NASDAQ listing qualifications after its consolidated closing bid price exceeded $1.00 for 10 consecutive days meeting the requirement of NASDAQ Marketplace Rule 4310(c)(8)(D).
